Manhattan BioSolutions secures non-dilutive angel funding

by Mbio2018|Published May 1, 2018

Manhattan BioSolutions establishes new laboratory space at the JLabs JNJ Innovation incubator in New York City

Published September 1, 2018

Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health

https://projectreporter.nih.gov/project_info_description.cfm?aid=9623199&icde=51409496&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC&pball= Project Number: 1R43CA228746-01A1 Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER

Published January 13, 2021

Manhattan BioSolutions to Present at the ACCESS CHINA Forum @JPM WEEK 2021

NEW YORK, NEW YORK, UNITED STATES, January 13, 2021 – Manhattan BioSolutions, Inc. (MABS), an emerging biotechnology company focused on the discovery […]

Published August 26, 2020

EVQLV and Manhattan BioSolutions Enter into Strategic Collaboration to Discover Novel Antibody-Based Therapies

New York, NY August 25, 2020—EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a strategic research collaboration with […]

Back to post list
Next post Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University